NRIX

Nurix Therapeutics, Inc.

22.84 USD

Last updated Oct 7, 19:45 UTC

Yesterday HIGH

$23.06

Yesterday LOW

$22.1

52w HIGH

$28.23

52w LOW

$9

EPS

-0.81

PE

-28.19

Next Earnings

Oct 20, 2026

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

Nurix Therapeutics, Inc. stock is down -12.61% since 30 days ago. The next earnings date is Oct 20, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 October’s closed higher than September. In the last 1 Unusual Options Trades, there were 1 CALL.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

15 Sep 13:43	15 Jan, 2027	21.00	CALL	50	202

Advanced Data Unlock

Benzinga Newsdesk

Thu Jul 9, 2026

Nurix Therapeutics Q2 EPS $(0.81) Misses $(0.74) Estimate, Sales $9.043M Miss $16.170M Estimate

Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.74) by 9.46 percent. This is a 55.77 percent decrease over losses of $(0.52) per share
Avi Kapoor

Tue Jun 30, 2026

Top 3 Health Care Stocks That May Keep You Up At Night In June

Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX, NRIX, GALT. Check BZ Edge Rankings for more.
Benzinga Insights

Thu Jun 25, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1 earnings came out
Benzinga Newsdesk

Thu Jun 18, 2026

Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $33

Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $26 to $33.
Benzinga Newsdesk

Mon Jun 15, 2026

Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target

Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $34 price target.
Benzinga Newsdesk

Thu Jun 11, 2026

Nurix Therapeutics shares are trading higher. The company announced it will present updated clinical data from ongoing NX-5948-301 Phase 1a/b clinical trial evaluating in patients with chronic lymphocytic leukemia at 2026 EHA Congress.
Benzinga Newsdesk

Thu Jun 11, 2026

Nurix to Present Updated CLL Drug Data at EHA 2026, Says Bexobrutideg Shows Durable Responses in CLL Trial

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced updated clinical
Benzinga Newsdesk

Wed Jun 10, 2026

HC Wainwright & Co. Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $32 price target.
Benzinga Newsdesk

Tue Jun 9, 2026

Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $32

Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $30 to $32.
Avi Kapoor

Tue Jun 9, 2026

Apple To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts change outlook on top names. B of A cuts CPB, UBS cuts AJG PT, B of A boosts ORCL PT, Needham raises APLD PT, Morgan Stanley raises AAPL PT, BTIG raises NRIX PT, GLJ Research raises CLF PT.